Acura Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2020
March 31, 2021 at 04:15 pm EDT
Share
Acura Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2020. For the quarter, the company reported total revenues of $718,000 against $1,220,000 a year ago. Operating loss was $131,000 against profit of $269,000 a year ago. Net loss was $243,000 or $0.01 per basic and diluted share against profit of $155,000 or $0.00 per basic and diluted share a year ago.
For the year, the company reported total revenues of $3,570,000 against $2,657,000 a year ago. Operating loss was $758,000 against $725,000 a year ago. Net loss was $1,208,000 or $0.04 per basic and diluted share against profit of $3,774,000 or $0.14 per basic and diluted share a year ago.
Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.
ACURA PHARMACEUTICALS, INC. 
